Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
IPO Year: 2021
Exchange: NASDAQ
Website: talis.bio
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2022 | $3.00 | Neutral → Underperform | BofA Securities |
| 9/27/2021 | $10.00 → $7.00 | Neutral → Underweight | JP Morgan |
| 8/31/2021 | Buy → Neutral | BTIG Research | |
| 8/12/2021 | $9.00 | Overweight → Neutral | Piper Sandler |
| 8/11/2021 | $17.00 → $10.00 | Overweight → Neutral | JP Morgan |